Bibliography
- SIMON LS: The treatment of rheumatoid arthritis. Best Pract. Res. Clin. Rheum. (2004) 18(4):507–538.
- ••Thorough update on the clinical use ofdisease-modifying anti-rheumatic drugs (DMARDs) and the biological response modifiers (BRMs) targeting IL-1 and TNF.
- STERRY WD, BOEHNCKE WH, BOS JD et al.: Biological therapies in the systemic management of psoriasis: international consensus conference. Br. J. Dermatol (2004) Suppl. 151(69):3–17.
- BROWN SJ, ABREU MT: Antibodies to tumor necrosis factor-a in the treatment of Chrohn's disease. Cuff. Opin. Drug Discov. Dev. (2005) 8(2):160–168.
- DAVIS JC: Breaking the ice: testing tumor necrosis factor a blockade in lupus. Arthritis Rheum. (2004) 50(10):3061–3063.
- HOLGATE ST: Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine (2004) 28(4-5):152–157.
- ADCOCK IM, CARAMORI G: Kinase targets and inhibitors for the treatment of airway inflammatory diseases. The next generation of drugs for severe asthma and COPD? Biodrugs (2004) 18(3):167–180.
- •Describes the clinical potential for inhibition of several signalling pathways in relation to two inflammatory diseases.
- KUMAR S, BLAKE SM: Pharmacological potential of p38 MAPK inhibitors. In: Handbook of Experimental Pharmacology (Inhibitors of protein kinases and phosphates) 167:65–83.
- ••A review of the potential of p38a MAPKinhibitors in various pathologies, with particular emphasis on inflammatory diseases.
- LEE JC, LAYDON JT, MCDONNELL PC et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739–746.
- ••The discovery of the molecular target forthe 4(5)-aryl-5(4)-pyridyl-imidazole anti-inflammatory agents, the first known p38 inhibitor class.
- JACKSON PF, BULLINGTON JL: Pyridinylimidazole based p38 MAP kinase inhibitors. Cuff. Topics Med. Chem. (2002) 2:1011–1020.
- CIRILLO PF, PARGELLIS C, REGAN J: The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Cum Topics Med. Chem. (2002) 2:1021–1035.
- DUMAS J: Protein kinase inhibitors from the urea class. Cum Opin. Drug Discov. Den (2002) 5(5):718–727.
- LEFTHERIS K, AHMED G, CHAN R et al.: The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase. J. Med. Chem. (2004) 47:6283–6291.
- ••A novel series of amides linked to a triazinecore. SAR and X-ray crystallography of an analogue with p38 is provided. A similar binding mode may be inferred for some related amides.
- REGAN J, CAPOLINO A, CIRILLO PF et al.: Structure-activity relationships of the p38a. MAP kinase inhibitor 1-(5-tert-buty1-2-p-toly1-2H-pyrazol-3-y1)-3-[4-(2-morphylin-4-yl-ethoxy)napth-thalen-1-yl]urea (BIRB 796).j Med. Chem. (2003) 46(22):4676–4686.
- ••SAR enzymology, preclinical pharmacology, and crystallography of the urea p38a inhibitors from Boehringer, including the clinical candidate BIRB-796 (see also ref. 27 therein).
- DUMAS J, HATOUM-MOKDAD H, SIBLEY RN et al.: Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor. Bioorg Med. Chem. Lett. (2002) 12:1559–1562.
- •SAR, of the urea p38a inhibitors from Bayer (see also ref. 4 therein).
- WAN Z, BOEHM JC, BOWER MJ et al.: N -Phenyl-N-purin-6-ylureas: the design and synthesis of p38a MAP kinase inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:1191–1194.
- • Describes acyclic urea p38 inhibitors which bind differently from the Boehringer series. In the present series the urea interacts directly with Met109.
- BOEHM JC, ADAMS JL: New inhibitors of p38 kinase. Expert Opin. Ther. Patents (2000) 10(1):25–37.
- KUMAR S, BOEHM J, LEE JC: p38 MAP diseases . Nat. Rev. Drug Discov. (2003) 2:717–726.
- FITZGERALD CE, PATEL SB, BECKER jw et al.: Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struct. Biol. (2003) 10:764–769.